## LLY: Eli Lilly and Company - XLV: Healthcare

### Executive Summary

VALUE thesis: PEG 0.90 indicates fundamental undervaluation. Quality metrics strong (ROE 96%, ROA 18%). Consistent execution (3/4 quarters beat estimates). Caution: momentum weakening (-9.1% MRS).

- **Horizon:** 20-60 days (position)
- **Risk Profile:** Lower - fundamental undervaluation
- **Stop Type:** Fixed 2xATR ($1000.11)
- **If Wrong:** Exit if fundamentals deteriorate or stop hit
- **Invalidation:** PEG > 1.5 or earnings miss

### News

- **Articles:** 10
- **Sentiment:** Bullish (Bullish: 6, Bearish: 0)

**1. Eli Lilly cuts Zepbound prices in competitive weight loss drug market battle**
- Source: Fox Business | 20251201T134300 | Somewhat-Bullish | Relevance: 99%
- Eli Lilly has announced new price cuts for its weight loss drug Zepbound through its LillyDirect platform to enhance patient access and compete in the growing weight loss drug market. Single-dose vials will now cost $299 per month for patients with valid prescriptions, with other doses also seeing significant reductions. This strategic move aims to leverage LillyDirect for direct-to-consumer sales, intensifying competition with rivals like Novo Nordisk.

**2. Eli Lilly Slashes Prices of Popular Weight-Loss Drug Zepbound**
- Source: NTD News | 20251201T203609 | Somewhat-Bullish | Relevance: 99%
-  Eli Lilly announced significant price reductions for its weight-loss drug, Zepbound, making it more affordable for patients purchasing through LillyDirect. The price cuts aim to increase accessibility to obesity treatments, especially as the company experiences financial success and federal initiatives push for broader drug price reductions. These moves are expected to influence the wider healthcare system and private insurance costs.

**3. Lilly Cuts Low-Dose Zepbound Price for Cash-Pay Buyers**
- Source: Bloomberg.com | 20251201T130000 | Neutral | Relevance: 99%
- Eli Lilly & Co. has announced a price cut of up to 20% for the introductory doses of its weight-loss drug Zepbound for cash-paying buyers. Starting Monday, the lowest dose will cost $299 a month, a $50 discount, while the next higher dose will be $399, marking a significant reduction to compete with rival Novo Nordisk A/S. The company is also lowering prices for higher doses by approximately $50.

**4. Jim Cramer Says Eli Lilly "May Have the Greatest Drug Franchise of All Time" With GLP-1 and Diabetes Medication**
- Source: Finviz | 20251129T132800 | Bullish | Relevance: 98%
- Jim Cramer highly praises Eli Lilly (LLY) for its GLP-1 medication, suggesting it could become the greatest drug franchise ever, not only for weight loss and diabetes but potentially for hypertension and alcoholism. He highlights Lilly's development of a more convenient pill version of the drug and a targeted shot that maintains muscle while attacking fat, positioning them ahead of competitors like Novo Nordisk. Cramer advises caution, however, despite his strong belief in the company's prospects.

**5. Eli Lilly Becomes First Trillion-Dollar Health Company**
- Source: Clinical Pain Advisor | 20251201T153609 | Bullish | Relevance: 98%
- Eli Lilly has become the first healthcare company globally to achieve a $1 trillion market value, driven largely by the success of its diabetes drug Mounjaro and weight-loss drug Zepbound. The company's stock has surged over 36% this year due to rising demand for its treatments, with Mounjaro and Zepbound generating billions in sales. Eli Lilly anticipates continued growth through expanded insurance coverage, new approvals, and the planned release of an oral weight-loss drug.

### Analyst Activity

**Target Signal:** BULLISH (Raises: 8, Lowers: 0)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-12-10 | Wells Fargo | $1200 | $1100 | +9% |
| 2025-12-04 | BMO Capital | $1200 | $1100 | +9% |
| 2025-11-24 | Morgan Stanley | $1290 | $1171 | +10% |
| 2025-11-24 | Bernstein | $1300 | $1100 | +18% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-12-10 | Wells Fargo | main | Overweight |
| 2025-12-04 | BMO Capital | main | Outperform |
| 2025-11-24 | Morgan Stanley | main | Overweight |
| 2025-11-24 | Bernstein | main | Outperform |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_SELLING** |
| Buys | 20 ($2.11M) |
| Sells | 30 ($207.96M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 45.8% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 7 / 3 |

**Top Holders:**
- Lilly Endowment, Inc: 10.1% (-0.5%)
- Vanguard Group Inc: 8.6% (+0.7%)
- Blackrock Inc.: 7.0% (-0.2%)
- PNC Financial Servic: 5.4% (+0.1%)
- State Street Corpora: 3.7% (+0.6%)

### Key Risks

1. Heavy insider selling: $208M sold (30 transactions in 90 days).
2. Market regime shift could impact momentum names disproportionately.
3. Sector rotation risk if leadership changes from current market theme.

### Catalysts

- Analyst target momentum: 8 raises (avg +12%) could attract flows.
- Broader market risk-on sentiment could lift quality names.

### Fundamentals

PEG ratio 0.90 indicates undervaluation relative to growth. Forward P/E 32.9x attractive for 36% earnings growth. Quality metrics strong (ROE 96%, ROA 18%, margin 31%). Balance sheet: $8.6B free cash flow. Analyst sentiment positive (8 raises, avg +12%). Insider selling cluster ($208.0M in 90 days), potential headwind. Institutional flow bullish (7 buying vs 3 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $890.8B |
| Beta | 0.37 |
| 52W Range | $623.78 - $1111.99 |
| Short Interest | 0.9% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 0.90 |
| Forward P/E | 32.9 |
| Current P/E | 44.7 |
| YoY Growth | 35.8% |
| EPS Direction | STABLE |

### Technicals

MRS_20 deteriorating from 12.5% to 3.5% (-9.1% in 5 days), indicating relative weakness vs NASDAQ. Below STRENGTH zone by 0.5pp (needs >4.0% for momentum thesis). MRS_5 (-2.9%) diverging from MRS_20 - short-term weakness emerging. AM_20 at 4.6% shows strong absolute momentum above own 20MA. Full SMA alignment bullish (above 20/50/200 SMAs).

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_20 | 3.45% (CS: 81) | Neutral |
| RSI_14 | 67.7 | Neutral |
| MACD Histogram | 0.10 | Bullish |
| vs SMA20 | 1.046x | Above |
| vs SMA50 | 1.190x | Above |
| vs SMA200 | 1.308x | Above |

### Decision

- **Verdict:** AVOID
- **Thesis:** VALUE

### Trade Setup

- **Entry:** $1057.89
- **Stop Loss:** $1000.11 (5.5% risk)
- **Target:** $1173.45 (R:R method)
- **Risk/Reward:** 2.00:1
- **Target Reasoning:** VALUE thesis targets 2.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 12
- **Position Value:** $12,694.68
- **Portfolio %:** 12.69%
- **Risk Dollars:** $750.00
- **Risk Per Trade:** 0.75%
- **Modifiers:** L1 100% | L2 75% | Combined 0.75x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.00x |
| L2 Sector | WEAKENING (Zone B) | 0.75x |

### Earnings

**Next:** 2026-02-05 (Est: $7.18)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $5.89 | $7.02 | +19.1% |
| 2025Q2 | $5.59 | $6.31 | +12.9% |
| 2025Q1 | $3.54 | $3.34 | -5.7% |
| 2024Q4 | $5.07 | $5.32 | +5.0% |

---
*RULE-based L3 | 2026-01-06 16:37 | MRS_20*